ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
September 17 2019 - 4:02PM
Business Wire
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical
company focused on the development and commercialization of
innovative medicines to address unmet medical needs in central
nervous system (CNS) disorders, today announced that it intends to
offer and sell, in an underwritten public offering and subject to
market and other conditions, $250,000,000 of its common stock.
There can be no assurance as to whether or when the offering may be
completed, or as to the actual size or terms of the offering.
BofA Merrill Lynch and J.P. Morgan Securities LLC are acting as
the joint book-running managers for the offering. ACADIA intends to
grant the underwriters a 30-day option to purchase up to an
additional $37,500,000 of its common stock.
The shares of common stock described above are being offered by
ACADIA pursuant to a shelf registration statement filed by ACADIA
with the Securities and Exchange Commission (SEC) that became
automatically effective on November 26, 2018. A preliminary
prospectus supplement related to the offering will be filed with
the SEC and will be available on the SEC’s website located at
http://www.sec.gov. Copies of the preliminary prospectus supplement
and the accompanying prospectus related to this offering, when
available, may be obtained from BofA Merrill Lynch, NC1-004-03-43,
200 North College Street, 3rd Floor, Charlotte, NC 28255-0001,
Attn: Prospectus Department, Email:
dg.prospectus_requests@baml.com, or from J.P. Morgan Securities
LLC, Attention: Broadridge Financial Solutions, 1155 Long Island
Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204, or by
email to: prospectus-eq_fi@jpmchase.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development
and commercialization of innovative medicines to address unmet
medical needs in central nervous system disorders. ACADIA has
developed and commercialized the first and only medicine approved
for the treatment of hallucinations and delusions associated with
Parkinson’s disease psychosis. ACADIA also has ongoing clinical
development efforts in additional areas with significant unmet
need, including dementia-related psychosis, major depressive
disorder, the negative symptoms of schizophrenia, and Rett
syndrome.
Forward-Looking Statements
Statements in this press release that are not strictly
historical in nature are forward-looking statements. These
statements include but are not limited to statements related to the
proposed offering of common stock by ACADIA. These statements are
only predictions based on current information and expectations and
involve a number of risks and uncertainties. Actual events or
results may differ materially from those projected in any of such
statements due to various factors, including market risks and
uncertainties and the satisfaction of customary closing conditions
for an offering of securities. For a discussion of these and other
factors, please refer to ACADIA’s annual report on Form 10-K for
the year ended December 31, 2018 as well as ACADIA’s subsequent
filings with the SEC. You are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the
date hereof. This caution is made under the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995. All
forward-looking statements are qualified in their entirety by this
cautionary statement and ACADIA undertakes no obligation to revise
or update this press release to reflect events or circumstances
after the date hereof, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190917006094/en/
Investor Contact: ACADIA Pharmaceuticals Inc. Mark Johnson, CFA
(858) 261-2771 ir@acadia-pharm.com
Media Contact: ACADIA Pharmaceuticals Inc. Maurissa Messier
(858) 768-6068 media@acadia-pharm.com
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Sep 2023 to Sep 2024